What Is Vesugen? Dosage, Half-Life & How to Track It
Also known as: Lys-Glu-Asp · KED · Khavinson vascular bioregulator
Vesugen is a synthetic tripeptide (Lys-Glu-Asp, or KED) developed at the Saint Petersburg Institute of Bioregulation and Gerontology, studied for effects on vascular endothelial cells. Protocols run it subcutaneously once daily, titrating weekly from 500 mcg up to a 1,500–2,000 mcg maintenance dose. Evidence comes from cell-based research, not human trials. Educational information only.
What Vesugen is and how it works
Vesugen is a synthetic tripeptide — lysine, glutamic acid, aspartic acid (Lys-Glu-Asp, abbreviated KED) — developed at the Saint Petersburg Institute of Bioregulation and Gerontology, the research group behind much of the Khavinson bioregulator family.
Its studied effect is on vascular endothelial cells — the cells lining blood vessels. Research suggests it supports endothelial cell proliferation through epigenetic regulation of Ki-67, a protein marker used to identify actively dividing cells. That fits the class-wide pattern for these peptides: a short sequence influencing gene expression in a specific tissue rather than acting like a conventional pharmaceutical.
As with the rest of this family, this is preclinical, cell-based evidence — not a human vascular-health trial. Vesugen is not FDA-approved, and there is no clinical data confirming any effect on blood vessels or cardiovascular markers in people.
Typical dosing & reconstitution
Vesugen is reconstituted with bacteriostatic water — a 20 mg vial mixed with 3.0 mL gives roughly 6.67 mg/mL, where one U-100 unit is about 66.7 mcg.
The titration ramps faster than most bioregulators on this list — week over week rather than every two weeks:
| Phase | Daily dose | Units (U-100) |
|---|---|---|
| Week 1 | 500 mcg | 7.5 units |
| Week 2 | 1,000 mcg | 15 units |
| Week 3 | 1,500 mcg | 22.5 units |
| Weeks 4–8+ | 1,500–2,000 mcg | 22.5–30 units |
Maintenance sits around 1,500 mcg/day once the ramp is done. The Week 1 dose (7.5 units) is small enough that a 50-unit insulin syringe reads it more accurately than a standard 100-unit one.
Half-life & what it means for frequency
No published pharmacokinetic study has measured Vesugen's half-life in humans. The once-daily, weekly-step titration is a protocol convention drawn from the preclinical research, not a calculated blood clearance curve.
The faster week-to-week ramp, versus the two-week steps used for some other bioregulators, doesn't reflect different pharmacokinetics — it is simply how the community protocol is structured. There is no data suggesting a slower or faster titration changes anything.
What to track & possible side effects
There is no dedicated human tolerability study for Vesugen. What is published is cell-based research into endothelial proliferation, which says nothing about side effects in a person taking daily subcutaneous injections.
Given the weekly dose changes, the practical thing to track is simply which week of the ramp you are on and the exact dose, so a four-week titration into an eight-week maintenance phase doesn't quietly drift.
How to track Vesugen in Stackeddd
Vesugen's dose changes every single week for the first month — log each shot so you never have to guess whether you're still on the 1,000 mcg week or already past it. Confirm the reconstitution math up front: at 6.67 mg/mL, the difference between 15 and 22.5 units is easy to eyeball wrong.
Model it yourself · free, no account
Reconstitution Calculator
Model it yourself: enter your vial size and BAC water and the Peptides tab returns concentration and exact units for any dose — the same math built into the Stackeddd app.
Related compounds
Related reading: Peptide reconstitution math: how much BAC water to add
Frequently asked questions
What is Vesugen?
Vesugen is a synthetic tripeptide (Lys-Glu-Asp, or KED) from the Khavinson bioregulator family, developed at the Saint Petersburg Institute of Bioregulation and Gerontology and studied for effects on vascular endothelial cells. It is not FDA-approved.
What is Vesugen used for?
Research suggests it supports vascular endothelial cell proliferation through epigenetic regulation of the Ki-67 gene marker. This comes from cell-culture studies, not human clinical trials.
How is Vesugen dosed?
Protocols titrate subcutaneously once daily, stepping up weekly from 500 mcg to a 1,500–2,000 mcg maintenance dose. A 20 mg vial reconstituted with 3.0 mL of bacteriostatic water gives about 6.67 mg/mL.
Is there human research on Vesugen and cardiovascular health?
No — the evidence is limited to cell-culture studies of endothelial cell proliferation. There is no human trial measuring cardiovascular or vascular outcomes.
This is educational information, not medical advice. Doses and protocols above reflect published references and community practice — protocol decisions belong with your prescribing physician. Generic names used throughout. How this reference is built & how the AI is tested →
STACKEDDD
Track it instead of guessing.
Doses, reconstitution, bloodwork, and an AI coach grounded in your own data — free to start, on the App Store and Google Play.